Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older.
Activities of daily living
Burden of illness
Burden of interference
Journal
The journals of gerontology. Series A, Biological sciences and medical sciences
ISSN: 1758-535X
Titre abrégé: J Gerontol A Biol Sci Med Sci
Pays: United States
ID NLM: 9502837
Informations de publication
Date de publication:
12 07 2019
12 07 2019
Historique:
received:
05
03
2018
pubmed:
30
6
2018
medline:
10
6
2020
entrez:
30
6
2018
Statut:
ppublish
Résumé
To determine the efficacy of an adjuvanted recombinant zoster vaccine in reducing the herpes zoster (HZ) burden of illness, HZ burden of interference with activities of daily living, and HZ impact on quality of life. The assessments were integrated in two Phase III trials, ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229). HZ burden of illness and HZ burden of interference with activities of daily living were assessed by the Zoster Brief Pain Inventory (ZBPI) instrument and quality of life by the EuroQol-5 Dimension (EQ-5D) utility index and the SF-36 health survey. We report the ZOE-50 results and a pooled analysis of patients aged 70 years and older from the trials combined. The estimated vaccine efficacy in reducing HZ burden of illness and HZ burden of interference was greater than 90% in both the ZOE-50 and the pooled ZOE-70 analysis. In confirmed HZ cases, adjuvanted recombinant zoster vaccine reduced the maximal ZBPI worst-pain score in the pooled ZOE-70 analysis (p = .032) and the maximal ZBPI average-pain scores in both the ZOE-50 (p = .049) and the pooled ZOE-70 analysis (p = .043). In breakthrough HZ cases, trends for diminished loss of quality of life compared with placebo-recipient HZ cases were observed, with differences up to 0.14 on the EQ-5D index at time points during the 4 weeks following HZ onset. Adjuvanted recombinant zoster vaccine reduced the HZ burden of illness significantly, particularly due to its very high vaccine efficacy in preventing HZ. For breakthrough HZ cases, the results suggest that the adjuvanted recombinant zoster vaccine mitigated severity of HZ-related pain, burden of interference with activities of daily living, and recipients' utility loss.
Sections du résumé
BACKGROUND
To determine the efficacy of an adjuvanted recombinant zoster vaccine in reducing the herpes zoster (HZ) burden of illness, HZ burden of interference with activities of daily living, and HZ impact on quality of life.
METHODS
The assessments were integrated in two Phase III trials, ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229). HZ burden of illness and HZ burden of interference with activities of daily living were assessed by the Zoster Brief Pain Inventory (ZBPI) instrument and quality of life by the EuroQol-5 Dimension (EQ-5D) utility index and the SF-36 health survey. We report the ZOE-50 results and a pooled analysis of patients aged 70 years and older from the trials combined.
RESULTS
The estimated vaccine efficacy in reducing HZ burden of illness and HZ burden of interference was greater than 90% in both the ZOE-50 and the pooled ZOE-70 analysis. In confirmed HZ cases, adjuvanted recombinant zoster vaccine reduced the maximal ZBPI worst-pain score in the pooled ZOE-70 analysis (p = .032) and the maximal ZBPI average-pain scores in both the ZOE-50 (p = .049) and the pooled ZOE-70 analysis (p = .043). In breakthrough HZ cases, trends for diminished loss of quality of life compared with placebo-recipient HZ cases were observed, with differences up to 0.14 on the EQ-5D index at time points during the 4 weeks following HZ onset.
CONCLUSIONS
Adjuvanted recombinant zoster vaccine reduced the HZ burden of illness significantly, particularly due to its very high vaccine efficacy in preventing HZ. For breakthrough HZ cases, the results suggest that the adjuvanted recombinant zoster vaccine mitigated severity of HZ-related pain, burden of interference with activities of daily living, and recipients' utility loss.
Identifiants
pubmed: 29955836
pii: 5046047
doi: 10.1093/gerona/gly150
pmc: PMC6625590
doi:
Substances chimiques
Adjuvants, Immunologic
0
Herpes Zoster Vaccine
0
Vaccines, Synthetic
0
Banques de données
ClinicalTrials.gov
['NCT01165177', 'NCT01165229']
Types de publication
Clinical Trial, Phase III
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1231-1238Informations de copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of The Gerontological Society of America.
Références
Ann Med. 2001 Jul;33(5):337-43
pubmed: 11491192
Clin Microbiol Rev. 2013 Oct;26(4):728-43
pubmed: 24092852
BMC Infect Dis. 2014 Jul 20;14:402
pubmed: 25038799
Pediatr Infect Dis J. 2006 Jan;25(1 Suppl):S42-7
pubmed: 16397428
N Engl J Med. 2005 Jun 2;352(22):2271-84
pubmed: 15930418
J Pain. 2004 Aug;5(6):344-56
pubmed: 15336639
Cost Eff Resour Alloc. 2010 Apr 30;8:7
pubmed: 20433704
Vaccine. 2014 Mar 26;32(15):1645-53
pubmed: 24534737
Z Gesundh Wiss. 2012 Aug;20(4):441-451
pubmed: 22822293
N Engl J Med. 2016 Sep 15;375(11):1019-32
pubmed: 27626517
J Pain. 2005 Jun;6(6):356-63
pubmed: 15943957
N Engl J Med. 2015 May 28;372(22):2087-96
pubmed: 25916341
Spine (Phila Pa 1976). 2000 Dec 15;25(24):3130-9
pubmed: 11124729
Stat Med. 1990 Dec;9(12):1447-54
pubmed: 2281232
BMC Med. 2010 Jun 21;8:37
pubmed: 20565946
Clin Infect Dis. 2012 Apr;54(7):946-54
pubmed: 22267715
Clin Infect Dis. 2004 Aug 1;39(3):342-8
pubmed: 15307000
Biometrics. 2009 Sep;65(3):885-93
pubmed: 19210727
Clin Infect Dis. 2001 May 15;32(10):1481-6
pubmed: 11317250
Vaccine. 2007 Nov 28;25(49):8326-37
pubmed: 17980938
Drugs Aging. 2016 Aug;33(8):575-83
pubmed: 27510615
Am J Clin Dermatol. 2005;6(5):317-25
pubmed: 16252931
Clin Infect Dis. 2011 Feb 1;52(3):332-40
pubmed: 21217180
CMAJ. 2010 Nov 9;182(16):1731-6
pubmed: 20921251
Z Gesundh Wiss. 2010 Aug;18(4):367-374
pubmed: 21124645